Safety of lornoxicam in G-6-PDH deficiency
Copyright policy )Safety of lornoxicam in G-6-PDH deficiency
To assess the safety of lornoxicam in subjects with G-6-PDH deficiency.Open controlled 2-week in vivo study on lornoxicam 8 mg bid in subjects with G-6-PDH deficiency suffering from rheumatic diseases.In 8 male patients with the Mediterranean form of G-6-PDH deficiency (mean age +/- SD, 54.3 years +/- 7.2) lornoxicam showed no influence on red blood cells (RBC) survival curve. The RBC half-life was the same before and after two weeks of treatment.Lornoxicam caused no RBC damage and evidenced favourable safety in subjects with G-6-PDH deficiency, suffering from rheumatic diseases.
Male, Time Factors, Arthritis, Anti-Inflammatory Agents, Non-Steroidal, R, Erythrocyte Aging, Middle Aged, RC31-1245, Piroxicam, Glucosephosphate Dehydrogenase Deficiency, Rheumatology, Medicine, Humans, Internal medicine
Male, Time Factors, Arthritis, Anti-Inflammatory Agents, Non-Steroidal, R, Erythrocyte Aging, Middle Aged, RC31-1245, Piroxicam, Glucosephosphate Dehydrogenase Deficiency, Rheumatology, Medicine, Humans, Internal medicine
selected citations These citations are derived from selected sources.This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).0 popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.Average influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).Average impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.Average
Citations provided by BIP!Popularity provided by BIP!